The historic rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its future within the broader market now presents questions about future returns . Alternative versions are diminishing exclusivity , prompting concerns that betting on companies heavily reliant to Viagra's once-dominant influence could be a problematic